rumor
    rumor
    • Screeners
    • Heatmaps
    • Charts
    • News
    • Documentation
    • Pricing
    • FAQ
    You're viewing limited data.
    Log inSign up

    Sign up

    24 hours of full access, free. No credit card.

    Log inPricing
    1 asset

    Market news

    TypeAll
    SortNewest
    Assets
    PBM
    Type
    TypeAll
    All
    Sort
    SortNewest
    Newest

    Filter by asset

      Psyence Biomedical invests $2.6m in PsyLabs after milestones met By Investing.com
      Oct 21Investing.comPBM
      Psyence BioMed Completes PsyLabs Investment as Ibogaine Milestones Are Met

      Ibogaine regulatory readiness pack completed and U.S. cGMP manufacturing agreement concluded with DEA-registered Benuvia in Texas; investment supports PsyLabs’ intended supply of pharmaceutical-grade ibogaine for the planned U.S. development programNEW YORK, Oct. 21, 2026 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) (“Psyence BioMed” or the “Company”) today announced that both milestones attached to its backstop subscription commitment in Psyence Labs Ltd. (“PsyLabs”) have been achi

      Oct 21Yahoo FinancePBM
      Psyence BioMed partners with Benuvia for ibogaine manufacturing
      Oct 6Investing.comPBM
      Psyence BioMed unit signs term sheet for U.S. ibogaine rights
      Sep 28Investing.comPBM
      Psyence BioMed Announces Exclusive U.S. Ibogaine Licence for Texas Ibogaine Research Corporation
      Sep 28Yahoo FinancePBM
      Psyence BioMed Agrees Up to $5 Million PsyLabs Investment and Forms Texas Ibogaine Unit

      Psyence Biomedical Ltd. (NASDAQ:PBM) has agreed to invest up to $5 million in Psyence Labs Ltd.

      Sep 23Yahoo FinancePBM
      Psyence BioMed invests up to $5M in PsyLabs, plans ibogaine trial By Investing.com
      Sep 23Investing.comPBM
      Psyence BioMed Announces Strategic Ibogaine Investment

      Transactions include an investment of up to US$5 million in PsyLabs and an approximately US$9 million value-matched share exchange Highlights The Company is actively advancing plans for a potential ibogaine clinical trial in Texas for Opioid Use Disorder (OUD).Texas Ibogaine Research Corporation (TIRC), a dedicated U.S. subsidiary of Psyence BioMed, has been established for its planned ibogaine development activities in the US.Psyence BioMed has agreed to invest up to US$5 million in PsyLabs, of

      Sep 23Yahoo FinancePBM
      Psyence BioMed Establishes Texas Ibogaine Research Corporation to Advance U.S. Ibogaine Development

      Texas-based company is designed to coordinate U.S. development, pharmaceutical-grade supply and potential clinical sponsorship activities through a dedicated Psyence BioMed entityHIGHLIGHTS Texas-based company established as dedicated U.S. vehicle for regulated ibogaine developmentPositioned to hold U.S. rights to PsyLabs’ pharmaceutical-grade ibogaine, subject to completion of definitive licensing arrangementsDesigned to coordinate supply, manufacturing, regulatory and potential clinical develo

      Sep 14Yahoo FinancePBM

      This is the newest page. Registered accounts read further back.